AIM Immunotech Inc. (identified in the supplied filing as Hemispherx Biopharma, Inc.) — 2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011; this is an annual report, not a standalone fourth-quarter filing. The company name in the filing differs from the company named in the request.
Business context
The company was a clinical-stage specialty pharmaceutical business developing immune-based therapies. Its principal products were experimental Ampligen for chronic fatigue syndrome (CFS) and other research uses; FDA-approved Alferon N Injection for certain genital warts, whose commercial sales had been halted since 2008; and experimental oral Alferon LDO for influenza.
Financial performance and position
| Metric | 2011 | 2010 |
|---|---|---|
| Revenue | $161,000 | $135,000 |
| Operating loss | $14.295 million | $16.387 million |
| Net loss | $9.015 million | $13.136 million |
| Net loss per share | $0.07 | $0.10 |
| Cash used in operating activities | $10.096 million | $11.886 million |
| Cash, cash equivalents and marketable securities | $34.391 million | $44.387 million |
| Working capital | $26.717 million | $33.842 million |
| Total assets | $43.513 million | $51.680 million |
| Debt, net of discount | $1.695 million | $0 |
Revenue came from Ampligen cost-recovery treatment programs; there were no commercial Alferon sales. Gross or operating margins are not meaningful to assess from the filing’s reported product revenue and costs, given the company’s minimal revenue and substantial development and manufacturing expenses. Accumulated deficit was $226.740 million.
Material changes versus 2010
- Net loss narrowed by $4.121 million, while operating loss remained substantial. Lower R&D, production and administrative expenses contributed; the reported loss also benefited from a $2.425 million non-cash warrant valuation gain and $2.272 million proceeds from selling New Jersey tax losses.
- Operating cash use fell by $1.790 million, but excluding the tax-loss sale proceeds, the filing says operating cash use increased by approximately $483,000 year over year.
- Cash and marketable securities declined by about $9.996 million. The balance included $3.101 million of restricted securities pledged as collateral for the margin loan.
- R&D expense decreased to $6.722 million from $7.613 million. G&A decreased to $6.691 million from $7.568 million, primarily due to lower legal fees.
Outlook, risks and unusual items
- Ampligen: The FDA had issued a Complete Response Letter, stating that the submitted studies did not provide credible evidence of efficacy and recommending at least one additional study, among other requirements. The FDA granted an additional response extension in January 2012. Approval, timing and additional development costs remained uncertain.
- Alferon: Management estimated sales might resume in the latter part of 2012, contingent on successful fill-and-finish work by Althea, FDA lot-release approval and manufacturing-facility regulatory status. Existing work-in-process had expiration dates from September 2012 to March 2013. The facility upgrade budget had been increased from $4.4 million to $6.5 million, with completion projected for mid-2012.
- Liquidity: Management said available resources were expected, but not assured, to fund operations for at least three years under anticipated needs. It warned that delayed commercialization or inability to restart Alferon sales could harm liquidity; further financing might be needed, and equity financing could be constrained or dilutive.
- Development uncertainty: Alferon LDO’s FDA-authorized Phase II study was delayed pending a confirmatory gene-expression study. Other clinical programs faced enrollment, partner, safety and regulatory uncertainties. The company had not generated significant product revenue or reported net income since 1987.
- Partnership and safety developments: Japanese partner Biken ended its Ampligen evaluation agreement, citing unresolved safety concerns based on a high-dose animal study; the company disputed that interpretation. A $188 million judgment against Johannesburg Consolidated Investments was being pursued in South Africa, but no gain was recorded. Other litigation included Cato Capital’s claims seeking up to $9.83 million plus other damages; the company said outcomes could not be estimated.
- Related-party disclosure: The company found prior disclosures about CEO William Carter’s relationship to Retreat House, LLC and its property ownership were inaccurate. Payments for property use were $137,200 in 2011 and $123,200 in 2010; the audit committee’s financial expert could not establish that the charges were reasonable. From November 2011, the CEO agreed that use of the property would incur no additional company charge, in connection with amended employment terms.
- Accounting and controls: The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective controls and no material weaknesses at year-end, despite identifying the prior related-party disclosure misstatement during 2011.
Important facts for investors to verify
- Confirm the issuer identity and filing period: the supplied document is Hemispherx Biopharma’s 2011 Form 10-K, not a filing under the requested AIM Immunotech name.
- Track FDA requirements and progress on the Ampligen NDA, including any new efficacy and safety study, its cost, duration and funding.
- Verify Alferon inventory completion, FDA lot-release decisions, facility recertification and whether commercial sales actually resumed.
- Reconcile cash and securities available for operations with restricted collateral, ongoing cash burn, capital-project spending and financing needs.
- Monitor litigation outcomes, including the Cato dispute and enforceability/collection of the South African judgment, and review subsequent related-party disclosures.
- Assess dilution exposure: the filing reported 135.6 million common shares outstanding at year-end and 22.6 million options and warrants outstanding.